NewLimit, based in South San Francisco, develops epigenetic reprogramming therapies that aim to restore youthful function to ageing cells, starting with the liver. It raised a $435 million Series C led by Founders Fund in June 2026, at a reported $3.1 billion valuation.
At a glance
| Price from | Custom |
| Best for | Investors and partners backing reprogramming therapies |
From NewLimit's own website.
What stands out
- Very large recent funding round
- Clear first clinical target
Worth knowing
- Still preclinical
- Reprogramming safety unproven in humans
How it ranks
NewLimit is ranked 2nd of 10 in Best Longevity Startups (Lister Score 95.6).
#2 in Best Longevity Startups · Lister Score 95.6
NewLimit says it plans a first Phase I trial of its liver reprogramming therapy in patients with fatty liver disease..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does NewLimit rank on Lister?
NewLimit is ranked 2nd of 10 in Best Longevity Startups (Lister Score 95.6).
Appears in
Add this badge to your site
If you work at NewLimit, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.